PARIS, June 30, 2015 /PRNewswire/ -- Pharnext SAS today announced that data related to its lead pleodrug PXT-3003, being developed for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four posters and one oral session at the 2015 Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress Center in Quebec City, Canada, June 27 - July 2, 2015.
At Poster Viewing Session 4, four posters will be presented on Wed July 1, 5p.m. to 7p.m. EDT:
Poster 23: "A Meta-Analysis Of Randomized Double-Blind Clinical Trials in CMT1A to Assess the Change from Baseline In CMTNS and ONLS Scales After One Year Of Treatment." Mandel J, et al. See publication in Orphanet Journal of Rare Diseases: http://www.ojrd.com/content/10/1/74/abstract.
Poster 35: "Design of the Next Phase III Trial Aiming to Confirm Efficacy and Safety of PXT-3003 in the Treatment of Charcot-Marie-Tooth Disease Type 1A." Scart-Grès C, et al.
Poster 57: "An Online Survey of Neurologists about Charcot-Marie-Tooth Disease Type 1A." Paoli X, et al.
Poster 62: "Baseline Analysis of PXT-3003 Phase 2 Data Reveals Two Blood Early Candidate Biomarkers for Therapeutic Response in CMT1A." Laffaire J, et al.
At the Plenary Lecture and Platform Session 3, on Mon June 29, 9:55 a.m. to 10:10a.m. EDT:
Oral Presentation (Poster 310): "An Experimental Trial of an Early Onset Treatment with a Combinational Drug (PXT-3003) Consisting of Baclofen, Naltrexone, Sorbitol in the CMT1A Rat Model." Prukop T, et al.; Presented by the Max Planck Institute as part of a collaboration with Pharnext.
Pharnext is an advanced clinical stage biopharmaceutical company developing novel therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological disorders. The proprietary research and development platform of Pharnext, based on network pharmacology, is applicable to a broad spectrum of diseases and allows the rapid development of "pleodrugs", synergistic combinations of repositioned drugs with established safety profiles. The company's two lead pleodrugs are PXT-3003 for the treatment of orphan disease Charcot Marie Tooth type 1A (Phase 2 clinical trial completed) and PXT-864 for Alzheimer's disease (Phase 2 clinical trial ongoing) and other neurologic indications (including Parkinson's disease and amyotrophic lateral sclerosis).
For further information, visit www.pharnext.com
Catherine Scart-Gres, M.D.
Chief Medical Officer
SOURCE Pharnext SAS